-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
TTP-8307
Category | Enterovirus (EV) |
CAS | 950225-08-8 |
Description | TTP-8307, a potent inhibitor of several rhino- and enteroviruses replication, inhibits coxsackievirus B3 (CVB3; EC50 = 1.2 μM) and poliovirus by interfering with the synthesis of viral RNA, and exerts antiviral activity through oxysterol-binding protein (OSBP). |
Product Information
Synonyms | Benzamide, N-[(1R)-1-(4-fluorophenyl)ethyl]-3-[2-(3-isoquinolinyl)-1H-imidazol-5-yl]-; N-[(1R)-1-(4-Fluorophenyl)ethyl]-3-[2-(3-isoquinolinyl)-1H-imidazol-5-yl]benzamide |
IUPAC Name | N-[(1R)-1-(4-fluorophenyl)ethyl]-3-(2-isoquinolin-3-yl-1H-imidazol-5-yl)benzamide |
Molecular Weight | 436.48 |
Molecular Formula | C27H21FN4O |
Canonical SMILES | CC(C1=CC=C(C=C1)F)NC(=O)C2=CC=CC(=C2)C3=CN=C(N3)C4=CC5=CC=CC=C5C=N4 |
InChI | InChI=1S/C27H21FN4O/c1-17(18-9-11-23(28)12-10-18)31-27(33)21-8-4-7-20(13-21)25-16-30-26(32-25)24-14-19-5-2-3-6-22(19)15-29-24/h2-17H,1H3,(H,30,32)(H,31,33)/t17-/m1/s1 |
InChIKey | SIBDJDZVNXVLEX-QGZVFWFLSA-N |
Boiling Point | 743.0±60.0°C at 760 mmHg |
Purity | ≥95% |
Density | 1.3±0.1 g/cm3 |
Solubility | Soluble in DMSO |
Appearance | White to light yellow (Solid) |
Storage | Store at -20°C |
Complexity | 654 |
Exact Mass | 436.16993947 |
In Vitro | TTP-8307 targets the nonstructural protein 3A, inhibits the replication of coxsackievirus B3 (CVB3 Nancy) with EC50 of 1.2 M. TTP-8307 inhibits the replication of coxsackievirus B3 and the three poliovirus Sabin strains, as well as coxsackieviruses A16 and A21 (EC50 of 0.85 and 5.34 μM). TTP-8307 inhibits human rhinoviruses (HRVs) 2, 29, 39, 45, 63, and 85. Mutations in the nonstructural protein 3A confer resistance to the novel enterovirus replication inhibitor TTP-8307. TTP-8307 inhibits OSBP-dependent viruses encephalomyocarditis virus (EMCV) and HCV. |
Target | Enterovirus; DNA/RNA Synthesis; HCV |
XLogP3-AA | 4.9 |